Other Agreements - Additional Information (Details) - USD ($)	3 Months Ended			9 Months Ended
	Sep. 30, 2016	Dec. 31, 2015	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Mar. 31, 2016
Other Agreements [Line Items]
Upfront consideration paid in exchange of common stock				5,587
Asset purchase agreement fixed payments paid for first two years	$ 740,000			$ 740,000
Percentage on annual revenues for cash consideration to be paid				6.00%
Asset purchase agreement aggregate cash compensation paid	$ 15,000,000			$ 15,000,000
Deferred payment obligation interest percentage	5.00%			5.00%
Discount rate used to calculate asset purchase obligation				2.50%
Debt instrument, amortization expense				$ 156,103	$ 229,232
Research and development	$ 1,910,116		$ 1,309,573	$ 6,515,808	2,951,009
Agreement expiration date				Oct. 31, 2019
Description on termination of agreement				The Company may terminate the agreement at any time upon 90 days’ written notice and may terminate any development plan under the agreement upon 30 days’ prior written notice. Illumina may terminate the agreement upon 30 days’ prior written notice if the Company undergoes certain changes of control. Either party may terminate the agreement upon the other party’s material breach of the agreement that remains uncured for 30 days, or upon the other party’s bankruptcy
Service Revenue	407,836		37,000	$ 1,991,567	150,292
Recognition of deferred revenue				160,106
Collaborative Arrangement
Other Agreements [Line Items]
Service Revenue	128,630			$ 158,192
LTC
Other Agreements [Line Items]
Agreement commencement period				2016-03
Non-cancellable purchase order value						$ 250,000
Agreement expiration date				2021-03
Automatic renewal term of agreement				2 years
Agreement termination notice period				60 days
Number of days material breach remains uncured				30 days
Bristol-Myers Squibb
Other Agreements [Line Items]
Agreement expiration date				May 11, 2019
Agreement termination notice period				90 days
Number of days material breach remains uncured				60 days
Illumina, Inc. Agreement
Other Agreements [Line Items]
Aggregate payment upon achievement of specified regulatory milestones	1,000,000			$ 1,000,000
Research and development		$ 100,000
Invetech PTY Ltd. Agreement
Other Agreements [Line Items]
Research and development	287,100		150,000	2,310,758	150,000
Growth Term Loan A
Other Agreements [Line Items]
Debt instrument, amortization expense	46,727		31,595	148,859	120,627
Minimum payments of pledged intangible assets due in 2014	868,750			868,750
Minimum payments of pledged intangible assets due in 2015	868,750			868,750
Minimum payments of pledged intangible assets due in first quarter of 2016	868,750			868,750
Minimum payments of pledged intangible assets due in second quarter of 2016	362,500			362,500
NuvoGen Asset Purchase Agreement
Other Agreements [Line Items]
Asset purchase agreement quarterly installments due in current year	543,750			543,750
Asset purchase agreement quarterly installments due in 2017	800,000			800,000
NuvoGen
Other Agreements [Line Items]
Convertible notes and related debt discount	127,518	$ 283,621		127,518
Debt instrument, amortization expense	51,636		$ 51,481	156,103	$ 229,232
Minimum | NuvoGen Asset Purchase Agreement
Other Agreements [Line Items]
Asset purchase agreement quarterly installments due from beginning 2018	$ 400,000			$ 400,000